Clinical and experimental dermatology · 2025
Exposure-response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT).
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wan Mandy, Jones Ashley P, Maskrey Daniel, Arenas-Hernandez Monica, Rosala-Hallas Anna, Beattie Paula E, Baron Susannah, Browne Fiona, Brown Sara J, Gach Joanna E, Greenblatt Danielle, Hearn Ross, Hilger Eva, Esdaile Ben, Cork Michael J, Howard Emma, Lovgren Marie-Louise, August Suzannah, Ashoor Farhiya, Williamson Paula R, McPherson Tess, O'Kane Donal, Ravenscroft Jane, Shaw Lindsay, Sinha Manish D, Spowart Catherine, Thomas Bjorn R, Sach Tracey H, Irvine Alan D, Flohr Carsten
Аннотация
This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg-1 daily) and methotrexate (0.4 mg kg-1 weekly) led to a significant reduction in disease severity scores over the 36-week treatment period. Higher trough ciclosporin concentrations were associated with lower disease severity scores and may serve as a useful tool for therapeutic drug monitoring of ciclosporin in CYP with AD. However, in contrast to a previously published study, steady-state erythrocyte-MTX-PG concentrations showed no significant association with treatment response. Drug concentrations were comparable between patients with and without drug-related adverse events.